Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.55 |
| ▸ | BCHE | P06276 | 5/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL7557991 | 1.00 | ACHE (0.55) | ACHEBCHECHRM4 | |
| SCHEMBL6989630 | 0.92 | ACHE (0.64) | ACHEBCHE | |
| Maleic Acid SCHEMBL27344003 | 0.91 | HRH3 (0.47) | ACHEBCHE | |
| SCHEMBL8299035 | 0.82 | ACHE (0.58) | ACHE | |
| Maleic Acid SCHEMBL6987772 | 0.82 | ACHE (0.84) | ACHEBCHECHRM4 | |
| Fumaric Acid SCHEMBL6987773 | 0.82 | ACHE (0.84) | ACHEBCHECHRM4 | |
| Maleic Acid SCHEMBL6986260 | 0.80 | ACHE (0.84) | ACHEBCHECHRM4 | |
| Maleic Acid SCHEMBL6986318 | 0.80 | ACHE (0.84) | ACHEBCHE | |
| Fumaric Acid SCHEMBL6986264 | 0.80 | ACHE (0.84) | ACHEBCHECHRM4 | |
| Fumaric Acid SCHEMBL7557843 | 0.80 | ACHE (0.84) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0646115-B1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-6498255-B2 | CHOLINESTERASE INHIBITORS; COGNITION ACTIVATORS; ALZHEIMER'S DISEASE; E.G., 3-(2-(1-(PHENYLMETHYL)-4-PIPERIDINYL)ETHYL)-1,2-BENZISOXAZOLE | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| US-20020028834-A1 | Heterocyclic-cyclic amine derivatives | VILLALOBOS ANABELLA (US) | 2002-03-07 | — | — | US | disclosed |
| US-6326382-B1 | CHOLINESTERASE INHIBITORS; USEFUL IN ENHANCING MEMORY IN PATIENTS SUFFERING FROM DEMENTIA AND ALZHEIMER'S DISEASE | EISAI CO., LTD (JP) | 2001-12-04 | — | — | US | disclosed |
| US-5538984-A | Methods of using piperidyl-benzisoxazole and benisothiazole derivatives as cholinesterase inhibitors | PFIZER INC. (US) | 1996-07-23 | — | — | US | disclosed |
| EP-0646115-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-04-05 | — | — | EP | disclosed |
| WO-1992017475-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | PFIZER INC. (US) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028834-A1 | Heterocyclic-cyclic amine derivatives | BCHE, ACHE, CHRM1 | ACHE 2/4885BCHE 1/4885CHRM4 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.